The NEJM study of 2,339 people without diabetes also found less knee osteoarthritis pain and fewer sleep apnea events on the drug than on placebo.
Recap by typeshit. Full story at DocWireNews.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
Rosario in Paris says the team's four AI-designed peptides looked right on paper but none reached the binding affinity they wanted, ending work begun in February.
Endpoints News
Corxel is the second drug developer in two weeks to choose a blank-check merger to go public, a route that had fallen out of favor.
Loading…